The potential of in vitro and ex vivo models to predict the efficacy of antifibrotic drugs

Pharmacology, Toxicology and Pharmaceutical Science

• Disease 100%
• Clinical Trial 100%
• Fibrosis 100%
• Imatinib 100%
• Galunisertib 100%
• Preclinical Study 50%
• Drug Screening 50%
• Kidney Fibrosis 50%
• Collagen Type 1 50%
• Dupuytren Contracture 50%
• Tissue Repair 50%
• Pirfenidone 50%
• Nintedanib 50%
• Verteporfin 50%
• Omipalisib 50%

Keyphrases

• Antifibrotic 100%
• Ex Vivo Model 100%
• Fibrosis 33%
• Imatinib 33%
• Myofibroblast 33%
• Galunisertib 33%
• Clinical Trials 16%
• Pirfenidone 16%
• Dupuytren's Disease 16%
• Repair Method 16%
• Predictive Power 16%
• Time Effect 16%
• Pharmacological Treatment 16%
• Developed Countries 16%
• Extracellular Matrix 16%
• Tissue Repair 16%
• Organ Failure 16%
• Repurposing 16%
• Fibroblasts 16%
• Fibrotic Diseases 16%
• Activated Fibroblasts 16%
• Human Trials 16%
• Scar Tissue 16%
• Healthy Tissue 16%
• Model Trial 16%
• Macromolecular Crowding 16%
• FDA-approved Drugs 16%
• Collagen Type I 16%
• Minimal Impact 16%
• Pathological Tissue 16%
• Culture Time 16%
• Verteporfin 16%
• Kidney Fibrosis 16%
• Drug Testing 16%
• Nintedanib 16%
• Omipalisib 16%